* Says to buy YM for $510 mln, or $2.95 per YM share
* To begin pivotal trial of YM’s drug in 2nd half of 2013 (Adds deal value including options; updates shares)
Dec 12 (Reuters) - Gilead Sciences Inc said it would buy Canada’s YM BioSciences Inc for about $510 million in cash, getting access to a second experimental drug to treat a rare blood and immune cell disorder.
Gilead shares closed down 0.14 percent at $76.23 on the Nasdaq, while YM’s U.S.-listed shares closed up 77 percent at $2.88, just under Gilead’s offer price.
YM’s only drug, codenamed CYT387, is being tested in patients with myelofibrosis, a blood disorder with limited treatment options.
Gilead, which is conducting mid-stage trials of its own drug for the disorder, said it will begin a pivotal late-stage clinical trial of CYT387 in the second half of 2013.
Shares of Incyte Corp, which sells the only approved drug to treat myelofibrosis, closed down 6 percent at $16.75 on news of Gilead’s deal with YM.
Incyte received $43.7 million from the sale of the drug, Jakafi, in the United States during July-September.
YM took hold of CYT387 with its acquisition of the Australian biopharmaceutical company Cytopia Ltd in 2010.
“It’s a good outcome for YM because they bought the product for a relatively modest amount, and a good fit for Gilead’s strategy of broadening its portfolio particularly in oncology,” Edison Investment Research analyst Christian Glennie said.
Gilead said it will pay $2.95 per YM share and that it plans to fund the acquisition with cash on hand. The deal would be valued at about $465 million based on YM’s outstanding shares, excluding options.
As of Sept. 30, YM had cash and short-term deposits of C$125.5 million ($127 million), according to a filing.
“While the valuation is less than the $4-$5 fair value we had assumed for YM, ... there is a relatively low probability another party enters with a higher bid,” Wells Fargo Securities analyst Brian Abrahams said in a note to clients.
The transaction is expected to close in the first quarter of 2013.
BofA Merrill Lynch and Bloom Burton & Co were financial advisers of YM, while Gilead was advised by Wilson Sonsini Goodrich & Rosati and Blake Cassels and Graydon LLP. ($1 = 0.9852 Canadian dollars) (Reporting by Adithya Venkatesan and Shounak Dasgupta in Bangalore; Editing by Roshni Menon, Don Sebastian, Maju Samuel)